Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit
Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit
复制标题
DOI：
10.1128/jcm.00557-20
复制
发表时间：
2020-06-01
影响因子：
9.4
通讯作者：
Greninger, Alexander L.
中科院分区：
文献类型：
--
作者：
Nalla, Arun K.;Casto, Amanda M.;Greninger, Alexander L.
从2019年12月开始，全球已知有近40万人感染了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。该病毒现已传播到包括美国在内的168个国家，在华盛顿的西雅图大都市区观察到了第一批病例。鉴于许多地区病例数量迅速增加，准确、高通量的SARS-CoV-2检测的可用性对于管理当前公共卫生危机的努力至关重要。在优化由华盛顿大学临床病毒学实验室（UW Virology Lab）进行的SARS-CoV-2检测的过程中，我们使用七种不同的引物探针组和一种检测试剂盒对检测进行了评估。我们发现，最敏感的测定是那些使用Corman等人（V.M. Corman，O. Landt，M.凯泽河，巴西-地Molenkamp等人，Euro Surveill 25：2000045，2020，https：//doi.org/10.2807/1560-7917.ES.2020.25.3.2000045）和CDC开发的N2集（Division of Viral Diseases，Centers for Disease Control and Prevention，2020，https://www.cdc.gov/coronavirus/2019-ncov/ downloads/rt-per-panel-primer-probes.pdf）。所有检测方法均对SARS-CoV-2具有高度特异性，无论使用何种引物探针组或试剂盒，在我们的分析中均未观察到与其他呼吸道病毒的交叉反应。这些结果将为其他临床实验室提供有价值的信息，这些实验室正在积极开发SARS-CoV-2检测方案，而此时全球迫切需要增加检测能力。
Nearly 400,000 people worldwide are known to have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) beginning in December 2019. The virus has now spread to over 168 countries including the United States, where the first cluster of cases was observed in the Seattle metropolitan area in Washington. Given the rapid increase in the number of cases in many localities, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we evaluated assays using seven different primer-probe sets and one assay kit. We found that the most sensitive assays were those that used the E-gene primerprobe set described by Corman et al. (V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, et al., Euro Surveill 25:2000045, 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set developed by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/ downloads/rt-per-panel-primer-probes.pdf). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer-probe set or kit used. These results will provide valuable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide.